Seguridad de las vacunas contra la COVID-19

Nataniel Aldo Chaparro Mérida; Dayany Moreno Samper; Alex Omar Franco Lacato

doi:10.17843/rpmesp.2021.384.9308

Authors

Nataniel Aldo Chaparro Mérida PROSALUD, Cochabamba, Bolivia.Médico; especialista en Inmunología https://orcid.org/0000-0001-6653-4142
Dayany Moreno Samper Hospital Clínico Quirúrgico Docente «Salvador Allende», Cuba.Médico; especialista en Inmunología; máster en asesoramiento genético https://orcid.org/0000-0003-2513-6265
Alex Omar Franco Lacato Universidad Franz Tamayo, Santa Cruz de la Sierra, Bolivia.Hospital Universitario San Juan de Dios, Santa Cruz de la Sierra, Bolivia.Médico; especialista en Inmunología https://orcid.org/0000-0001-6653-4142

DOI:

https://doi.org/10.17843/rpmesp.2021.384.9308

Keywords:

Vaccine, Coronavirus, SARS-CoV-2, Spike Glycoprotein, Immunogenicity, Efficacy, Adverse events, Clinical Trial, Phase III, Pandemics

Abstract

The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.